Abstract: Molecular-genetic imaging in living organisms has become a new field with the exceptional growth over the past 5 years. Modern imaging is based on three technologies: nuclear, magnetic resonance and optical imaging. Most current molecular-genetic imaging strategies are "indirect," coupling a "reporter gene" with a complimentary "reporter probe." The reporter transgene usually encodes for an enzyme, receptor or transporter that selectively interacts with a radiolabeled probe and results in accumulation of radioactivity in the transduced cell. In addition, reporter systems based on the expression of fluorescence or bioluminescence proteins are becoming more widely applied in small animal imaging. This review begins with a description of Positron Emission Tomography (PET)-based imaging genes and their complimentary radiolabeled probes that we think will be the first to enter clinical trials. Then we describe other imaging genes, mostly for optical imaging, which have been developed by investigators working with a variety of disease models in mice. Such optical reporters are unlikely to enter the clinic, at least not in the near-term. Reporter gene constructs can be driven by constitutive promoter elements and used to monitor gene therapy vectors and the efficacy of gene targeting and transduction, as well as to monitor adoptive cell-based therapies. Inducible promoters can be used as "sensors" to monitor endogenous cell processes, including specific intracellular molecular-genetic events and the activity of signaling pathways, by regulating the magnitude of reporter gene expression.
Introduction and background
Molecular imaging can be defined as a visualization of cellular processes in space and time at the molecular level. It has its roots in molecular and cell biology as well as in imaging technology, chemistry and radiochemistry. For many years researchers used reporter genes encoding enzymes, such as bacterial β-galactosidase (lacZ gene) [1] and chloramphenicol acetyltransferase (CAT gene) [2] , to study various cellular processes. However, 'visualization' of these enzymes required post-mortem tissue sampling and processing for precise quantitative analysis. Advances in cell biology and especially in its clinical applications dictate developments of novel visualization systems, which would not only provide accurate and sensitive measurements, but would allow doing this in living cells and live animals and humans.
Three different non-invasive, in vivo imaging technologies have developed in parallel: (1) nuclear imaging [quantitative autoradiography (QAR), gamma camera and positron emission tomography (PET)] [3, 4] ; (2) optical imaging of small animals [5, 6] ; (3) magnetic resonance (MR) imaging [7, 8] . Radionuclide-based imaging is founded on the radiotracer principle, first described by George de Hevesy. In 1935 he published a letter in Nature on the tracer principle using 32 P for the study of phosphorus metabolism [9] and he was awarded the Nobel Prize in Chemistry in 1943. The tracer technique was later adapted for many applications in physiology and biochemistry, as well as in functional diagnosis and use in nuclear medicine and molecular imaging.
Before discussing specific issues related to reporter genes, it would be helpful to briefly outline three currently used strategies for non-invasive monitoring and quantification of gene expression named as "direct", "indirect" and "biomarker" imaging [10] [11] [12] [13] . Direct molecular imaging strategies are usually described in terms of a specific target and a target-specific probe. The imaging of specific antigens on the cell surface with radiolabeled antibodies or genetically engineered antibody fragments (minibodies) is an example of direct molecular imaging that has evolved over the past 30 years [14] . In addition, widely used in vivo visualization of receptor density/occupancy with small radiolabeled ligands can be also classified as a direct imaging [15] [16] [17] [18] . These two examples represent some of the first molecular imaging applications used in clinical nuclear medicine. However, direct imaging strategies are limited by the necessity to develop and validate a specific probe for each molecular target. Since each probe requires detailed characterization including sensitivity, specificity and safety, time and cost for new probe development can be considerable. For example, the development, validation and regulatory approval for [19, 20] .
Indirect imaging strategies are more complex. One example of indirect imaging that is now being extensively used is reporter gene imaging. It requires "pre-targeting" (delivery) of the reporter gene to the target tissue by transfection, transduction or by cell delivery. The reporter gene usually includes transcriptional control components that can function as "molecular-genetic sensors" and regulate or initiate reporter gene expression. This strategy has been widely applied in optical [21] [22] [23] and radionuclide-based imaging [24] [25] [26] [27] [28] and to a lesser degree in magnetic resonance (MR) imaging [7, 29, 30] .
A general paradigm for non-invasive reporter gene imaging using radiolabeled probes was initially described in 1995 [24] and is shown in Fig. 1 . This paradigm requires the appropriate combination of a reporter/marker transgene and a reporter/marker probe. The reporter transgene usually encodes for an enzyme [26] , receptor [31] or transporter [32] that selectively interacts with a radiolabeled probe resulting in the accumulation of radioactivity in the transduced cell. In addition, reporter systems based on the expression of fluorescence proteins (broadly used in cell culture and embryogenesis studies [33] are becoming widely applied in small animal imaging studies [34] .
Biomarker or surrogate-marker imaging can be used to assess downstream effects of single or several endogenous molecular-genetic processes. This approach is particularly attractive for potential translation into clinical studies in the near-term because existing radiopharmaceuticals and imaging models may be useful for monitoring downstream effects of alterations in specific cellular pathways that occur in various diseases. A recent example of it in a clinical setting was the biomarker imaging for "early" assessment of treatment response is [ 18 F]-FDG PET imaging of gastrointestinal stromal tumors (GIST)
pre-and post-STI571 (Gleevec) treatment [35] . However, it remains to be shown whether there is a sufficiently high correlation between biomarker imaging and direct molecular assays that reflect the activity of a particular molecular/genetic pathway of interest.
Reporter genes encoding enzymes
In this review, we will emphasize the development of reporter genes for non-invasive quantitative imaging in small animals and the potential for translation of comparable studies to patients. One focus will be animal models of cancer and the potential for novel studies in patients with cancer. In addition, there are several opportunities for reporter gene studies in other genetically based human diseases. We will start with a description of PET/SPECT (single photon emission computed tomography) based reporter imaging genes and the complimentary probes that probably will be the first candidates in clinical trials. We will then describe other reporter genes, mostly for optical imaging, which have been developed by investigators working with xenografts and transgenic animal models of cancer. The optical reporters are unlikely to enter the clinic, at least not in the near-term, due to the effects of scatter and attenuation on transmittance light through tissue. The reporter gene is transfected into target cells by a delivery system (e.g., a virus). The reporter gene product can be either cytoplasmic or nuclear enzyme. The imaging probe, a radioactive tracer, must cross the cell membrane and be converted within cytoplasm or nucleus to a product which is "trapped" within the cell (the most commonly used enzymatic reaction is phosphorylation). (B) A transporter incorporated into the cell membrane can also be the product of transgene gene expression, thus concentrating the imaging probe in the cells expressing the reporter gene. (C) Alternatively, a receptor on the cell surface can be expressed by transgene. The imaging probe as a ligand can bind the receptor, resulting in the accumulation of the imaging probe in the transduced tissue. The probe concentration is usually proportional to the concentration of the reporter gene product, therefore this system can be appropriate for a study of different cellular processes which involve macromolecular interactions, including regulation of transcription, translation, post-translational protein modification and protein degradation. Abbreviations: RTracer -Radiotracer; RLigand -radioligand; HSV1-TK/HSV1-sr39TK -herpes simplex virus thymidine kinase/ herpes simplex virus -serine 39 mutant thymidine kinase; hNET -human norepinephrine transporter; hNIS -human sodium iodide symporter; SSTr -somatostatin receptor; D2R -dopamine D2-like receptor; FIAU -2'-deoxy-2'-fluoro-5-iodo- [37, 38] .
In the mid 1990's, a number of potential marker/reporter probes for imaging HSV1-tk gene expression were studied at Memorial Sloan-Kettering Cancer Center (New York, NY, USA) ( Fig. 2A) . FIAU had been previously radiolabeled for imaging viral infections [39] . After in vitro determinations of HSV1-TK sensitivity and selectivity for FIAU, this compound was proved to have good imaging potential. Attractively, a variety of radionuclides ( 11 C, 124 The first series of imaging experiments involving HSV1-tk transduced tissue and FIAU were performed in rats bearing intracerebral (i.c) RG2 tumors using QAR imaging techniques [25] (Fig. 3A, B ). This was subsequently followed by gamma camera, SPECT and PET imaging studies (Fig. 3C) [25, 26] . The preliminary findings in a phase I/II clinical trial of gene therapy for recurrent glioblastoma illustrated that PET-imaging of HSV1-tk expression in patients is feasible and that vector-mediated gene expression may predict the therapeutic effect [40] .
PET imaging of HSV1-tk expression can be also performed with acycloguanosine derivatives which show very low affinity to mammalian TK-1. Radiolabeled with shortlived Fluorine-18 (t 1/2 = 110 min), these compounds can be applied for repetitive imaging studies (every 6 to 8 h 
Imaging of endogenous biological processes
Additional applications of HSV1-tk as a reporter gene include the imaging of endogenous biological processes. Such non-invasive imaging of the transcriptional regulation of endogenous genes in living animals may provide a better understanding of normal and cancer-related biological processes. For example, our group has demonstrated that p53, hypoxia inducible factor 1 (HIF-1) and transforming growth factor β (TGF β1) dependent gene expression can be imaged in vivo with PET and by in situ fluorescence [47] [48] [49] .
For these experiments, retroviral vectors were generated by placing a dual-reporter fusion gene HSV1-tk/GFP under control of a specific response element for p53, HIF-1, or Smads/Runx2 transcriptional factors complexes. Upregulation of these transcriptional factors was assessed and correlated with the expression of dependent downstream genes (p21, VEGF) (Fig. 4) . These results also show that PET imaging of p53, HIF-1 and [25] .
Smads/Runx2 transcriptional activity in different model xenografts could be used for assessing the effects of new drugs or other therapeutic agents that are mediated through these pathways in variety of animal models [47] [48] [49] [50] . Gene expression is also regulated by post-transcriptional events, including translation of mRNA. One such example is the regulation of the dihydrofolate reductase (DHFR) expression. Several studies indicated that the DHFR binds to its own mRNA in the coding region and that inhibition of DHFR by methotrexate (MTX) releases the DHFR enzyme from the mRNA. Consequently, this release results in an increase in translation of DHFR. In addition to the described translational regulation of DHFR in cancer cells exposed to MTX, increased levels of DHFR also occur through DHFR gene amplification, a common mechanism of acquired resistance to this drug. In contrast to rapid translational modulation of DHFR, gene amplification occurs in response to chronic exposure to antifolates and elevated cellular levels of DHFR resulting from transcription of multiple DHFR gene copies. Recently, Philipp Mayer-Kuckuk et al., have shown that this adaptive cellular response mechanism was due to post-transcriptional regulation of gene expression and could be monitored by reporter-PET imaging [50, 51] . The results of this study indicated that the increase in reporter protein and enzyme (DHFR-HSV1-TK) activity was observed at the translational level, rather than at the transcriptional level. This effect was imaged by [ 124 I]FIAU and PET; the studies were performed on nude rats bearing DHFR-HSV1-TK-transduced HCT-8 xenografts.
Imaging of cell trafficking
Additional applications of HSV1-tk as a reporter gene include the non-invasive and repetitive imaging of adoptively administered immune cells. The imaging of lymphocyte trafficking dates back to the early 1970's, when the first experiments were performed with extracorporeal labeling of lymphocytes [52, 53] using various metallic radioisotopes (e.g., 111 In, 67 Co, 64 Cu, 51 Cr, 99m Tc) [52] [53] [54] [55] [56] . There are several problems associated with ex vivo labeling of lymphocytes:
(1) the relatively low level of radioactivity per cell, (2) the exposure of cells to higher doses of radioactivity during labeling, (3) the short period for cell monitoring, which is limited by radioactivity decay and biological clearance. Stable genetic labeling of lymphocytes with various reporter genes has been used to avoid the temporal limitations of in vitro radio-or magnetic labeling of cells. Retroviralmediated transduction has proven to be one of the most effective methods to deliver transgenes into T-cells resulting in high levels of sustained transgene expression [57, 58] . For example, this technique was used to deliver transgenes for detection of a long-term circulation of the Epstein-Barr virus (EBV) specific cytotoxic donor-derived T-cells in patients treated for post bone morrow transplantation EBV-induced lymphoproliferative diseases. The transduced T-cells with neomycin resistance or low-affinity nerve growth factor receptor and HSV1-tk genes were detectable in peripheral blood samples from patients by PCR or Fluorescences Activated Cell Sorting (FACS) analysis [59] [60] [61] . Genetic labeling of lymphocytes can be also achieved with the luciferase (Luc) reporter gene. In the recent studies, the distribution of cytotoxic T-lymphocytes (CTL) was monitored over time using bioluminescence of FLuc-expressing CTLs [62, 63] . However, bioluminescence imaging is a semi-quantitative assay at best, because signal intensity depends largely on distance from the surface and on the variable optical characteristics of different tissues. Better quantification can be achieved by radiotracer-based gamma camera imaging. This method has been used to monitor adoptively transferred antigen-specific T cells transduced with the fusion reporter gene (HSV1-tk/GFP gene) [64] . In this study, SCID mice bearing four different tumors were treated with HSV1-TK/GFP transduced EBV specific CTLs. Specific accumulation and localization of radioactivity was observed only in the autologous and allogeneic HLA-A0201 + EBV-BLCL tumors; no T cell infiltration was seen in the allogeneic HLA-A0201-matched, EBV-negative B-ALL or HLA-mismatched EBV BLCL xenografts. Sequential imaging over 15 days after T cell injection permitted long term monitoring of the HSV1-TK/GFP transduced cells and demonstrated tumor-specific migration and targeting of the CTLs. Infusion of EBV-specific cytotoxic T-cells (CTLs) led to the elimination of subcutaneous autologous EBV-BLCL tumor and HLA-A0201 + allogenic EBV-BLCL xenografts [64] . These experiments demonstrate feasibility of repeated visualization of transferred T cells over time using non-invasive reporter gene PET imaging with its potential transfer in clinical studies in patients with EBV+ cancer.
3 Genes encoding transporters
Sodium iodide symporter gene
Radioactive iodide ( 131 I) therapy is one of the approaches used in the treatment of human thyroid cancer. Thyrocytes are physiologically capable of accumulating iodine because of the presence of the sodium iodide symporter (NIS) in their plasma membranes [65] . NIS is also expressed at lower levels, in many other organs including the salivary and lacrimal glands, stomach, kidney epithelial cells and placenta [66, 67] . NIS is an intrinsic membrane glycoprotein with 13 putative transmembrane domains transporting two sodium ions with one iodide ion across the cell membrane [68] . NIS can transport many other anions coupled with sodium, such as ClO
. Since cloning of the NIS gene in 1996 [65] , NIS was considered an attractive imaging reporter gene [32, 70] . There are several distinct advantages for using NIS as a reporter gene. First, NIS is not a foreign gene; thus, it is non-immunogenic. Second, the tissue expression distribution of endogenous NIS protein is limited; as a result, imaging of exogenous NIS function can be performed in a variety of tissues due to limited background expression (stomach and thyroid are major exceptions). Third, NIS mediates the uptake of simple radiopharmaceuticals; therefore, complicated syntheses and labeling of substrate molecules is not required for imaging. Fourth, most of the radiotracers are specific only to NIS-expressing cells; therefore, background signal is significantly reduced. Fifth, both NIS-mediated radiotracer uptake and background radioactivity clear are rapid, ideally suited for non-invasive imaging.
The human NIS (hNIS) gene has been used in various vectors to produce stable transduced cell lines. High iodide uptake levels have been achieved in such transduced cells and their xenografts [32, [71] [72] [73] . A distinctive feature of the bidirectional NIS symporter is the rapid washout of iodide from virtually all cells, except thyrocytes bearing thyroperoxidase. In normal thyroid tissue, thyroperoxidase iodinates thyroglobulin tyrosine residues and incorporates iodine atoms into thyroid hormone and this results in the accumulation of radioactive iodine in these cells. In an attempt to overcome the rapid excretion of radioiodide from NIS-transfected tumors, the thyroperoxidase -TPO gene was co-transduced into tumor cells [74] . The transfection with both human NIS and TPO genes resulted in some increase in radioiodide uptake and retention and an enhanced rate of tumor cell apoptosis, but this has not been consistently achieved.
Sodium iodide symporter gene as a therapeutic gene
NIS can serve as both a therapeutic and a reporter gene. Non-invasive imaging of therapeutic transgenes provides the opportunity to modify the therapy directed at transfected cells or tumors. Such an approach was proven successful by recent experimental 131 Itherapy of NIS-transfected myeloma in SCID mice [75] . High (up to 18-fold) transgene expression in transduced myeloma cells, with negligible expression in other cells were the key contributors of this successful application. Remarkably, myeloma xenografts containing both wild-type and hNIS expressing cells could be imaged with a gamma camera and completely eradicated with a single therapeutic dose of 131 I-iodide, without recurrence for up to 5 months after therapy. The treatment was successful even though hNIS was not transduced into every myeloma cell [75] . The likely explanation of this response is that non-transduced cells were killed by radioactivity emitted by 131 I-iodide from neighboring cells, the so-called "by-stander" effect [76, 77] . Progress in the molecular and functional characterization of NIS during the last few years has clearly created new opportunities for the development of diagnostic and therapeutic applications for NIS [78] [79] [80] . These applications are especially relevant to nuclear medicine imaging and for the prospect of using administered radioisotopes in a highly targeted fashion to effectively destroy a wide variety of cancer cells by internal, rather than external, radiation. The first transfer of the hNIS gene into tumors for targeted radiotherapy was performed with a recombinant adenovirus, AdNIS, where the expression of the rat NIS gene was under the control of the constitutive cytomegalovirus promoter [32] .
Sodium iodide symporter gene as a reporter gene
Another application of hNIS as a reporter gene in adenoviral vectors was demonstrated by myocardial gene transfer imaging in living rats using radioiodide and gamma-camera [81] . In this study, a dual-gene adenovirus that expresses both NIS protein and enhanced green fluorescent protein (EGFP) (Ad.EGFP.NIS) was injected into the myocardium of living rats. Following 123 I scintigraphy demonstrated clear focal myocardial uptake at the Ad.EGFP.NIS injection site. Histologic analysis confirmed the co-localization of 123 I radioactivity, EGFP fluorescence and NIS staining. To develop a molecular imaging method suitable for monitoring viable cancer cells, another dual-imaging reporter gene system was constructed from 2 individual reporter genes, sodium iodide symporter (NIS) and luciferase [82] . In parallel, our group has developed a self-inactivating retroviral vector containing a dual-reporter gene cassette (hNIS-IRES2-GFP) with the hNIS and GFP genes, separated by an internal ribosomal entry site (IRES) element; the expression cassette was driven by a constitutive CMV promoter. A stably transduced rat glioma (RG2) cell line was generated with this construct and used for in vitro and in vivo imaging studies of 
Imaging of endogenous biological processes
Control of hNIS gene expression by endogenous transcription factors is actively being investigated and has led to the development of novel strategies to image signaling pathway activity in cancer cells using hNIS as a reporter gene. hNIS expression can be controlled by a number of promoter elements. For instance, So et al. [83] used the NIS reporter gene for imaging retinoic acid receptor activity controlled by an artificial cis-acting retinoic acid responsive element [83] . Recently, the same group has shown that p53 expression can be monitored both in vitro and in vivo using the NIS reporter gene in a cis-p53RE-hNIS construct [79] . They have also shown a possibility to develop a (NIS)-transgenic mouse in which NIS is constitutively expressed as an imaging reporter gene exclusively in cardiomyocytes [84] . For production of NIS-transgenic mice, NIS was placed under the alpha-myosin heavy chain (alpha-MHC) promoter. The heart of the transgenic mouse was clearly and intensely visible on microPET using 124 I. Such transgenic mouse can be used as an imaging model for cardiomyocyte-specific reporter gene expression and cellular differentiation into cardiomyocytes after cardiac stem or progenitor cell transplantation [84] .
Norepinephrine transporter gene as a reporter gene
In recent years, several groups have been evaluating the norepinephrine transporter (NET) as a potential reporter gene for in vivo imaging [85, 86] . NET is a transmembrane protein consisting of approximately 600 amino acids which mediates the transport of norepinephrine, dopamine and epinephrine across the cell membrane. NET cDNAs have been cloned from multiple species including human [87] , rat [88] and mouse [89] . In humans, NET is encoded by a single gene of 16 exons [90] . Topological predictions indicate that NET and its homologs bear 12 transmembrane domains (TMD) with a large Nglycosylated extracellular loop between TMD 3 and 4 and intracellular NH2 and COOH termini. NET gene expression in human, rat and likely other species is subject of alternative pre-mRNA splicing [88, 91, 92] . It has been shown that NET isoforms encode a different COOH termini in various species [88, 93] . The characterization and comparison of bovine NET variants [94] emphasized the importance of the cytoplasmic-part of the COOH terminus for intracellular trafficking of NET. It was suggested that the COOH termini may be involved in substrate binding, although it seems dispensable for the binding of inhibitors of transport. Another group subsequently demonstrated that the COOH terminus of human NET (hNET) C-t var2 contains an additional consensus motif for a PKC-phosphorylation site [95] . Thus, the differences observed in the transport kinetics between hNET and hNET C-t var2 may be partly due to a differential phosphorylation of the COOH termini of these isoforms [95] . The expression of hNET is restricted to the central and peripheral sympathetic nervous system (brain, heart) [96] [97] [98] . The main advantage of using NET as a reporter gene is that NET expression can be imaged efficiently using meta-iodobenzylguanidine (MIBG), a clinically approved, metabolically stable artificial analog of norepinephrine. MIBG can be readily labeled with different iodine radio-isotopes ( 123 I, 124 I, 125 I, 123 I).
This tracer was developed in 1980 for imaging of the peripheral sympathetic nervous system [99] . It is also an established clinical tracer for the diagnosis of tumors originating from the sympathetic nervous systems (neuroblastoma and pheochromocytoma). MIBG is characterized by a favorable biodistribution for whole body imaging with rapid, mainly renal, excretion of unbound tracer [100] . Furthermore, MIBG uptake is highly specific for NET expression. The human origin of NET makes this reporter a good candidate for clinical applications and the non-invasive monitoring of gene-and cell-based therapy due to its non-immunogenicity. Recent study took advantage of constitutive expression of bovine NET gene for visualization of A431 epithelioid carcinoma cells and HT1080 fibrosarcoma cells [101] . Gamma-camera images obtained after 24 hours of [
123 I]MIBG injection clearly showed the accumulation of radioactivity in A431NET tumors. MIBG uptakes in vitro and in vivo were even higher in NET-transduced tumor cells than in the PC12 pheochromocytoma cells which represent a standard model for cells naturally expressing NET. The effect of hNET gene transfection was investigated in several cell lines (COS-1, HeLa and glioblastoma cells); a 3-, 9-and 15-fold increase in uptake was achieved with 131 I-MIBG, respectively, compared to non-transduced wild-type cells [102, 103] . Another study was performed with rat Morris hepatoma cells transduced with a retroviral vector bearing two constitutive expressed genes (hNET and puromycin genes). After puromycin selection, the expression of a functional norepinephrine transporter was demonstrated by the uptake of 3 H-noradrenaline and 131 I-MIBG [86] . The accumulation of MIBG was 36-fold higher in transduced cells than in wild-type cells. The scintigraphic images of nude mice bearing both wild-type and hNET-expressing Morris hepatoma tumors, confirmed the in vitro data. However, in vivo results obtained from rats bearing hNET-expressing tumors, were inconsistent with those obtained from nude mice. The researchers speculated that the transport of MIBG can be influenced by a variety of processes and factors, such as Nglycosylation of the transport protein, perfusion and competition of the substrate with naturally occurring catecholamines [104, 105] . Given that plasma levels of catecholamine are even higher in mice than in rats, competition seems not to be the reason for the lack of MIBG accumulation in rats [106, 107] . The production of inactivating antibodies against the hNET gene product in rats receiving transplants, but not in immune-deficient nude mice is possible and thus should be investigated further. hNET imaging can be also done using another probe, 11 C-m-hydroxyephedrine (mHED). 11 C-mHED is structurally closely related to norepinephrine and has been used as a PET tracer for the assessment of presynaptic sympathetic nerve terminals [108] .
11 C-mHED has demonstrated highly specific uptake and retention in sympathetic nerve terminals of the heart. The radiotracer shares the same neuronal uptake mechanism as norepinephrine, but it is resistant to metabolism by monoamine oxidase and catechol-O-methyltransferase [109] . It was found that the retention of 11 C-mHED in hNET-expressing tissue is the result of rapid hNET-mediated reuptake of the tracer. A rapid clearance of 11 C-mHED reflects its rapid renal excretion [85] . But the short half-life of carbon-11 (20 min) might be a disadvantage.
Genes encoding receptors

Somatostatin receptor gene as a therapeutic and reporter gene
Somatostatin, originally detected in the hypothalamus of rats, is a peptide that inhibits the release of growth hormone. It was subsequently shown to be a 14 amino acid cyclic peptide [110, 111] . Somatostatin belongs to a phylogenetically ancient, multigene family of peptides with two important bioactive products: somatostatin-14 and somatostatin-28. Somatostatin modulates neurotransmission in the central nervous system (as a neuro-transmitter) and regulates the release of growth hormone and thyrotropin (as a neurohormone). It also has a regulatory role in the gastrointestinal tract, as well as in the exocrine and endocrine pancreas. When synthesized and released into the gastrointestinal tract and pancreas, somatostatin acts in an autocrine and paracrine manner to inhibit glandular secretion. In addition, somatostatin regulates neurotransmission, smooth-muscle contractility and absorption of nutrients [112] . The various actions of somatostatin are mediated through specific membrane receptors somatostatin receptors (SSTRs), which have been demonstrated in various regions of the brain, anterior pituitary and leptomeninges, the endocrine and exocrine pancreas and the mucosa of the gastrointestinal tract, as well as in cells of the immune system [113] . There are six SSTRs (types 1, 2A and 2B, 3, 4 and 5) and they all belong to a seventransmembrane domain family of receptors associated with G-proteins. Expression of the type 2 somatostatin receptor (SSTr2) occurs primarily in the pituitary gland with high affinity for octreotide. Octreotide is an 8-amino-acid peptide; it was the first synthetic somatostatin analogue introduced for clinical use. It inhibits the release of growth hormone, glucagon and insulin more effectively, than somatostatin-14 [114] . Octreotide is more stable and resistant to in vivo degradation than the endogenous 14-amino-acid somatostatin peptide. Octreotide has been labeled with 111 In and 99m Tc and successfully used for gamma-camera and SPECT imaging of endogenous SSTr2 expression in tumors [115, 116] 
Dopamine D2 receptor gene as a reporter gene
Dopamine (DA) is the predominant catecholamine neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, cognition, emotion, positive reinforcement, food intake and endocrine regulation. The five subtypes of dopamine receptors, D1 to D5 have been identified. They are members of a seven-transmembrane-spanning heterotrimeric GTP-binding protein (G protein)-coupled receptor (GPCR) family. They can be further subdivided into D1-like (D1 and D5) and D2-like (D2, D3, D4) receptors based on DNA sequence similarity [119] . The D2 receptor is a 415 amino acid protein that is expressed at highest levels in striatum and pituitary [120] . This receptor interacts with 3-(2'-[18F]fluoroethyl)spiperone (FESP), a radiolabeled probe that was developed to image dopominergic neurons [121] . FESP can be synthesized at high specific activity and is currently used for SPECT and PET imaging of D2 receptor in human neurodegenerative diseases such as Parkinson's disease [122] . The dopamine D2 receptor can also be used as a reporter gene in non-neural tissue that has little or no D2R expression [123] . However, expression of ligand-binding receptors could alter the signaling pathways of target cells and lead to a reduction in the level of cyclic AMP. This problem was resolved by substitution of amino acid 80 from Asp to Ala in the D2 receptor (D2R80A) [124] . The mutant protein lacks the ability to be regulated by cyclic AMP, but retains the affinity for FESP. This was elegantly demonstrated in a correlation study using a bi-cistronic adenoviral vector carrying both the mutated receptor and HSV1-sr39tk genes [125] . A potential problem associated with the strong expression of membrane proteins as reporter gene products, is proper protein folding, intracellular trafficking and insertion of these proteins into the plasma membrane so they retain their function. Despite these concerns, it is clear that quantitative determination of the D2 receptor expression can be performed in vivo with FESP.
Optical imaging genes
Optical-based (bioluminescence and fluorescence) reporter systems are receiving increased attention because of their efficiency for sequential imaging, operational simplicity and substantial cost benefits (Fig. 6 ).
Bioluminescence imaging
Bioluminescence imaging is based on the detection of visible light produced during enzymatic (luciferase) oxidation of a specific substrate (luciferin). Important for reporter gene bioluminescence imaging, the intensity of emitted light (photon/sec) should be proportional to the level of enzyme (luciferase) being expressed. Furthermore, bioluminescence should only be detected in the presence of enzyme and not in the presence of substrate (e.g., luciferin) alone. Bioluminescence based reporter systems are being extensively used in many laboratories for various in vitro assays and whole body imaging of small animals [ 21, 22, 49, 62, 126, 127] . The most studied systems are those belonging to beetles in the family Lampyridae, more commonly known as fireflies and Renilla Luciferase produced by Renilla reniformis, a sea pansy that displays bioluminescence upon mechanical stimulation [128, 129] . Bioluminescence is widely distributed in nature, occurring in a remarkably diverse set of organisms. Phylogenetic analyses suggest that bioluminescence has had more than 30 independent origins. Luciferin and luciferase are generic terms, but all of luciferases don't exhibit sequence homology between the classes. While the most commonly used bioluminescence reporters for research purposes have been Firefly and Renilla luciferases, useful luciferases have also been cloned from jellyfish (Aequorea), sea copepod (Gaussia; GLuc), corals (Tenilla), click beetle (Pyrophorus plagiophthalamus) and several bacterial species (Vibrio fischeri, V. harveyi ). To be an optimal reporter for bioluminescence imaging all reporter genes were modified according most favorable codon usage in mammalian cells and were called humanized variants of luciferases. The growth of applications of bioluminescence is currently stimulating research into investigation and development of a new bioluminescence systems. Since the cloning of the Firefly luciferase gene in 1985, this enzyme has been a very useful tool for in vivo and in vitro studies of gene regulation. Firefly luciferase (FLuc) or humanized variant (hFLuc) produce photons only in the presence of ATP, magnesium and the substrate luciferin, by an oxidative reaction.
Another most commonly occurring natural bioluminescence system depends on derivatives of imidazolopyrazine that have been found in seven phyla and approximately 90 genera, including copepods, ostracods, cephalopods and amphipods. Coelenterazine {2-(phydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo [1, 2-a]pyrazin-3-(7H)-one} is an imidazolopyrazine derivative that acts similar to luciferin. When oxidized by the appropriate luciferase, coelenterazine produces carbon dioxide, coelenteramide and light. The emitted light is blue and across a broad range, peaking at 480 nm, in vitro. Renilla Luciferase was first purified and characterized by Matthews et al. [130] from a bioluminescent soft coral that displays blue-green bioluminescence upon mechanical stimulation. Later the Renilla Luciferase (hRLuc) gene was cloned and expressed in Escherichia coli and is currently a part of a number of commercial assay systems [130, 131] .
Gaussia princeps is a marine copepod which emits bioluminescence in response to variety of stimuli. The luciferase responsible for this reaction and its corresponding gene (Gluc) has recently been cloned from G. princeps. GLuc is a small monomeric protein composed of 185 AA (19.9 kDa) with a short coding sequence (555 bp); it can oxidize coelenterazine to produce light. The humanized form of Gaussia luciferase (hGLuc) was expressed in mammalian cells following viral delivery. It was found to be nontoxic and naturally secreted in the culture medium. Humanized GLuc (hGLuc) is very heat stable and strongly resistant to acidic and basic conditions. hGLuc generates stronger signal intensity from cells in culture (1000-fold) compared with hRLuc and hFLuc. Despite the fact that a significant portion of hGLuc is secreted, its intracellular bioluminescence from viable cells or cell lysate is still over 100-fold higher compared to hRLuc or hFLuc [132] . In vivo experiments under standard conditions had shown that hGLuc has 200-fold higher bioluminescent signal intensity than hRLuc and intensity comparable to that of hFLuc [132] .
The Gluc luciferase was used as a bioluminescence reporter of DNA hybridization and is a promising detection reagent for immunoassays and mammalian cells in culture [132, 133] .
Other potential bioluminescence imaging systems are based on bacterial luciferases. For example, Vibrio harveyi luciferase catalyzes a green-blue light emission reaction, utilizing reduced FMN (flavin mononucleotide) (FMNH 2 ), a long chain aliphatic aldehyde and O 2 [134, 135] . This bioluminescence reaction needs further study and characterization prior to their use in reporter gene studies.
As with nuclear and magnetic resonance reporter systems, bioluminescence imaging depends on the delivery of a specific substrate to the cells expressing the reporter gene. The Firefly and Renilla luciferase reporter systems and their corresponding luminescence substrates (luciferin and coelenterazine) have several advantages for imaging small living animals. First, their background light emission is low thus providing very high sensitivity and specificity of the imaging [136] . Second, it is feasible to directly correlate the photon emission flux (light intensity) to reporter gene expression and to the level of reporter gene product; namely, luciferase, if luciferin, ATP and oxygen levels are not the rate determining factors, but rather are present in excess at near saturation levels. Despite a number of positive features it is now recognized that luciferases, utilizing coelenterazine, have two drawbacks. First of all, there is a substantial autoluminescence of coelenterazine in the presence of certain proteins, particularly albumin [137] . In addition, MDR1 transporter can rapidly export coelenterazine from cell lines that express this protein, therefore reducing the total photon emission flux [138] .
The main benefit of optical bioluminescence imaging is that it can be used to detect very low signal levels (≈ 300 cells can be detected) due to extremely low background. However, the efficiency of light transmission through an animal is limited due to light absorption and scatter and depends on tissue type. Light emission from firefly luciferases occurs over a broad-band (480-613 nm) and peaks at 560 nm and is greatly influenced by hemoglobin absorption. Hemoglobin absorbs primarily in the blue and green part of the visible spectrum, therefore greatly reducing the signal. This characteristic, coupled with the optical properties of biological tissue, allows the light of firefly luciferases to penetrate through only a few centimeters of tissue [139] . Recently, a study has shown the effect of temperature on the spectral profile and brightness of different luciferases. For example, the peak emission wavelength of Fluc was shifted to the red part of the spectrum when the temperature was increased from 25 to 37
• C. Light from enzymes with spectral peaks in the orange/red wavelengths (≈ 590 to 650 nm), for example click beetle red (CBRed) luciferase, is absorbed less and penetrates deeper through tissues [140] . Red-shifted reporter systems have greater applicability for measuring biological processes that occur in deep tissues. One disadvantage of bioluminescence imaging is the lack of 3-D information because the cooled CCD camera produces two-dimensional images. However, it is expected that future bioluminescence image acquisition devices using rotating CCD cameras may allow volumetric imaging, especially when combined with novel red-shifted luciferases that have better tissue penetration.
Fluorescence imaging
In the last 10 years, green fluorescent protein (GFP) has evolved from a virtually unknown protein to a common reporter protein broadly used in molecular and cell biology. It is particularly useful because of its stability and the fact that its chromophore (formed by autocatalytic cyclization) does not require a cofactor. Fluorescent protein-based reporter gene systems originated with different spectral-shifted variants of Aequorea victoria GFPs [141] [142] [143] [144] . During last 5 years several GFP homologues have been cloned from Anthozoa, Hydrozoa and Copepoda species, demonstrating the broad evolutionary and spectral diversity of this protein family. A few recent reviews describe fluorescent protein variants, their properties, advantages and limitations [145, 146] . Significant progress has been achieved in modification and optimization of fluorescent proteins across the whole visible spectrum for their efficient expression, improved optical characteristics and maturation speed. Currently, native fluorescent proteins and their mutant variants cover a wide spectrum from 450 to 650 nm (Table 1 ) and include cyan, green, yellow and orange-red color classes. TurboGFP, which is an improved variant of green fluorescent protein cloned form copepoda Pontellina plumata, is one example of such modified proteins [147] . In contrast to native GFP, TurboGFP does not aggregate in longterm cultures and demonstrates fast protein maturation allowing early signal detection. Mutagenesis of YFP, a natural yellow fluorescent protein from Phialidium sp., resulted in a new PhiYFP protein which fluoresces much brighter than YFP. The PhiYFP gene has also been successfully used in fusion reporter constructs [147] . Several natural red fluorescent proteins have been cloned: eqFP611-from sea anemone Entacmaea quadricolor [148] ; drF586, also known as DsRed -from colallimorpharian Discosoma sp. [148] ; and JRedbased on Anthomedusae jellyfish purple chromoprotein [147] . Employing of DsRed as a genetically encoded fusion tag has been limited because of two critical problemsobligate tetramerization and incomplete maturation. Several attempts have been made to overcome these shortcomings including genetic modification and creation of DsRed2 and DsRed-Express (T1) proteins. Significant progress has been achieved in resolving the problem of tetramerization by transforming DsRed into a far-red dimer HcRed1, which was generated on the basis of the chromoprotein from Heteractis crispa [149] . Roger Y. Tsien's group have presented the stepwise evolution of DsRed to a dimer and then either to a genetic fusion of two copies of the protein, i.e., a tandem dimer, or to a true monomer designated mRFP1 (monomeric red fluorescent protein) [150] . Recently, the same group has reported the development of a novel mutant mRFP monomeric fluorescent protein called mPlum with an emission wavelength 649 nm, which is 37 nm longer than the peak of the original mRFP and 12 nm beyond the previous tandem dimer t-HcRed1 [151] .
Several photoactivable fluorescent proteins have appeared over the past few years (Table 2 ). These proteins are capable for photoconversion from cyan to green fluorescent form (PS-CFP, a mutant variant of GFP-like protein cloned form Aequorea coerulescens and it's improved PS-CFP2 variant); for reversible photoswitch from non-fluorescent to red fluorescent form (KFP-Red based on Anemonia sulcata chromoprotein) or from green to non-fluorescent form (Dronpa-genetically engineered fluorescent protein isolated from Pectiniidae); for irreversible conversion from a green to red fluorescent state (Kaede tetrameric protein and monomeric mutant mEosFP from Trachyphyllia) after exposure to light irradiation of a specific wavelength [152] [153] [154] [155] [156] . Typically fluorescence intensity increases many times during photoactivation.
Fluorescence imaging has been shown to be useful for various in vitro applications, such as: 1) monitoring the gene expression, 2) tracking of the protein of interest: its expression, localization, movement, interaction and functional activity in the cell, 3) Table 2 Properties of photoswitchable fluorescent proteins.
identifying and selecting transduced cells by FACS analysis and sorting, 4) tracking the movement of labeled cells, proteins and different organelles using photoswitchable proteins [152] and 5) cost-effective in vitro assays for validation of the function and sensitivity of specific inducible reporter systems.
In addition, fluorescence imaging could be one of the key technologies in the whole body imaging, which can be applied for visualization of reporter gene expression [5, 34] and studies of interactions between proteins [157] or target-gene promoter regulation [158] . Such studies, based on fluorescence and bioluminescence resonance energy transfer (FRET/BRET) -a technology that involves the non-radiative transfer of energy between the donor and acceptor molecules, may provide real-time information on the kinetics of the interacting partners [157] . Unquestionable advantage of the fluorescent techniques is a possibility to examine tissue sections at the microscopic level by in situ fluorescence imaging [11, 34, 159] .
Despite rather promising performance, fluorescence imaging suffers serious setbacks. Both transmitted and emitted light are attenuated and scattered by tissue thus significantly limiting the resolution and depth of the body imaging. Endogenous autofluorescence of tissues also negatively contributes to the imaging quality and depth frequently resulting in a substantial background emission that limits the sensitivity and specificity of fluorescence imaging. Although the latter problem can be addressed by the use of selective filters or the application of spectral analysis, the light penetration problem is more difficult to solve. A possible solution is a development of new classes of red fluorescent proteins and near-infrared dyes which provide better deep tissue imaging characteristics [149, 150, 160] . It is also worth mentioning that fluorescent imaging requires an external source of light for activation of the chromophore.
Strong intensity, absence of autobioluminescence and subsequently low background activity makes in vivo bioluminescence reporter imaging more sensitive than in vivo fluorescence reporter imaging and often determines a choice of the system to be used in the experiments. In addition, luciferase is well suited to monitor fast events, for instance transcription, due to its relatively fast induction [161] and to the short half-life of both luciferin and luciferase. However, this advantage over the longer-lived GFP has recently been mitigated by the development of short-lived, rapidly degradable variants of GFP. These short-lived variants have been used for higher temporal resolution imaging of GFP chimeric proteins within the cells [162, 163] . On the other hand, combination of two or three different reporter genes in a single fusion gene could provide additional tools for the analysis of cells both in vivo and ex vivo.
Issues for the future
Non-invasive reporter gene imaging is an indirect imaging strategy that can be fully exploited in experimental and transgenic animals. However, reporter gene imaging applications will be more limited in patients due to the necessity of transducing target tissue with specific reporter constructs. Ideal vectors for targeting specific organs or tissue (tumors) in patients do not exist at this time, although vector development is a very active area of human gene therapy research. Each new vector (and imaging probe) requires extensive validation and time-consuming safety testing prior to approval for human administration. However, once a reporter-gene and reporter-probe combination has been validated and approved for human studies, this reporter-gene can be used in many different systems and vectors. A number of human genes are being considered as potential reporter genes and several are likely to be used in future human reporter gene applications. Nevertheless, direct imaging probes will be actively developed owing to their advantages and they will make significant contributions to the field of molecular imaging. A major advantage of direct imaging probes is that once developed and validated, they do not require the transduction of target tissue by a reporter gene-bearing vector.
The development of versatile and sensitive assays that do not require tissue sampling will be of considerable value for monitoring molecular-genetic and cellular processes in animal models of human disease. Translation of similar imaging paradigm to human subjects is likely to become feasible in the near future. The benefits of non-invasive monitoring (imaging) of transgene expression in gene therapy protocols are substantial; it will provide a practical and clinically useful way to monitor gene transduction and expression in target (and non-target) tissue over time. This is particularly true for adoptive therapy protocols where reporter genes can be used to not only monitor the distribution, targeting and persistence of administered cells, but can also be used to monitor the activation and functional status of these cells. An objective and quantitative measure of the level and duration of therapeutic gene expression over time, or the targeting, persistence and functional activity of adoptively transferred cells is a critical goal that can be related to therapeutic outcome.
